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Abstract
Introduction:  There  is  a  recognized  increase  of  lifelong  surgery  risk  in  Crohn  disease  (CD).
Outcome  data  concerning  surgery  in  children,  particularly  in  the  biological  era,  are  limited.
Aim: To  characterize  the  clinical  proﬁle  and  the  clinical  outcome  in  children  and  adolescents
with CD  who  underwent  surgical  intervention,  in  a  single  tertiary  referral  center.
Methods: Retrospective,  cross-sectional  study,  including  pediatric  patients  with  CD  undergoing
intra-abdominal  surgery  in  the  last  11  years.
Results:  Included  eight  of  50  CD  total  patients  (16%);  six  female;  median  age  at  CD  diagno-
sis of  12.0  years;  Paris  classiﬁcation:  (a)  location:  ileocolonic  (5),  colonic  (1),  upper  disease
(1), ileocolonic/upper  disease  (1);  (b)  behavior:  stricturing  (4),  nonstricturing  nonpenetrating
(2), penetrating  (1),  both  penetrating  and  stricturing  disease  (1);  growth  delay  (2).  Six  children
received thiopurines,  ﬁve  mesalazine,  three  corticosteroids  and  four  anti-TNF  therapy,  preoper-
atively. Surgery  followed  diagnosis  by  a  median  of  2.9  years.  Median  PCDAI  at  the  time  of  surgery
was 35.0.  Elective  surgery  was  performed  in  six  patients  and  emergency  surgery  in  two,  without
major complications.  Five  children  received  anti-TNF  and  three  thiopurines  post-operatively.
Within the  follow-up  period  (median  1.7  years),  relapse  occurred  in  one  child  (3.2  years  after
intervention);  the  remaining  seven  patients  persist  in  clinical  remission.  Median  PCDAI  in  the
last evaluation  was  6.3.  Weight  and  height  recovery  was  observed  in  seven  patients,  at  last
follow-up.
Conclusion:  Surgical  treatment  of  CD  is  a  valid  alternative  in  selected  cases,  contributing  to  the
resolution  of  acute  complications  and  maintenance  of  remission,  allowing  disease-free  interval
and nutritional  recovery.
©  2016  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
r  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/an open  access  article  unde
by-nc-nd/4.0/).∗ Corresponding author.
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2341-4545/© 2016 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cirurgia  na  Doenc¸a de  Crohn  Pediátrica:  Série  de  Casos  de  um  Centro  de  Referência
Terciário
Resumo
Introduc¸ão:  É  reconhecido  o  risco  aumentado  de  cirurgia  ao  longo  da  vida  na  populac¸ão  com
doenc¸a de  Crohn  (DC).  Contudo  os  estudos  publicados  em  idade  pediátrica  são  ainda  escassos,
particularmente  na  era  dos  biológicos.
Objetivos:  Caraterizar  o  perﬁl  evolutivo  da  populac¸ão  pediátrica  com  DC  submetida  a  cirurgia
num centro  de  referência.
Métodos:  Estudo  retrospetivo,  transversal,  doentes  pediátricos  com  DC  submetidos  a  cirurgia
intra-abdominal  no  período  de  11  anos.
Resultados:  8/50  doentes  com  DC  (16%);  seis  raparigas;  idade  mediana  ao  diagnóstico  12,0
anos; Classiﬁcac¸ão  de  Paris:  a)  localizac¸ão:  ileocólica  (5),  cólica  (1),  proximal  (1);  ileocólica  e
proximal (1);  b)  comportamento:  estenosante  (4),  não  estenosante  não  penetrante  (2),  pene-
trante (1),  estenosante  e  penetrante  (1);  atraso  de  crescimento  (2);  terapêutica  pré-cirurgia:
tiopurinas  (6),  mesalazina  (5),  corticóides  (3)  e  agentes  biológicos  (4).  Mediana  do  PCDAI  à  data
da cirurgia  35,0.  O  timing  cirúrgico  mediano  foi  2,9  anos  após  o  diagnóstico.  Foram  efetuadas
cirurgias eletivas  em  seis  doentes  e  de  emergência  em  dois,  sem  complicac¸ões.  No  período  após
cirurgia, a  terapêutica  de  manutenc¸ão  incluiu:  biológicos  (5)  e  tiopurinas  (3).  No  período  de
seguimento  (mediana  1,7  anos),  ocorreu  recidiva  numa  crianc¸a  (3,2  anos  após  a  intervenc¸ão);  as
restantes persistiram  em  remissão  clínica;  PCDAI  mediano  na  última  avaliac¸ão  6,3.  Observou-se
recuperac¸ão ponderal  e  estatural  em  sete  doentes,  na  última  avaliac¸ão.
Conclusão:  O  tratamento  cirúrgico  da  DC  representa  uma  alternativa  válida  em  casos  sele-
cionados,  contribuindo  para  a  resoluc¸ão  de  complicac¸ões  agudas  e  manutenc¸ão  da  remissão,
permitindo  um  intervalo  livre  de  doenc¸a  e  recuperac¸ão  nutricional.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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of  CD  established  according  to  Porto  Criteria,15 undergo-. Introduction
rohn  disease  (CD)  at  pediatric  age  is  recognizably  associ-
ted  with  signiﬁcant  morbidity,  with  growth  and  nutritional
mpairment.  New  epidemiological  data  indicate  that  the
ncidence  of  CD  in  this  speciﬁc  age  group  is  continually  ris-
ng,  with  up  to  25%  of  patients  with  inﬂammatory  bowel
isease  being  diagnosed  before  age  20.1--3 In  Portugal,  a
ecent  pharmaco-epidemiological  study,  based  on  regional
ntestinal  anti-inﬂammatory  drugs  consumption,  estimated
n  incidence  of  CD  pediatric  patients  of  6.7/100,000
hildren/year.4
This  chronic  relapsing  disease  may  have  devastating
ffects  on  patient’s  quality  of  life  with  need  for  long-term
herapy,  frequent  hospitalizations  and  consultations.5
The  medical  therapy  of  CD  has  dramatically  changed  over
he  past  decade,  with  the  increasing  use  of  early  anti-TNF,
oth  in  children  and  adulthood.  However,  it  remains  to  be
lucidated  the  true  impact  of  this  therapy  in  disease  natural
ourse  and  the  need  of  surgery.
It  has  been  estimated  that  the  total  life  time  risk  of
urgery  in  CD  adult  patients  is  between  50%  and  70%.6 Gupta
t  al  reported  that  the  cumulative  incidence  of  surgery  in
 pediatric  population  was  17%  at  5  years  and  28%  at  10
ears  after  diagnosis.  In  this  study,  the  main  risk  factors
or  the  ﬁrst  surgery  were  the  presence  of  abscess,  ﬁstula
r  stricture  and  poor  growth  at  presentation.7 Furthermore,
od2/CARD15  gene  variants  which  play  an  important  role
n  the  susceptibility  to  CD,  may  also  be  associated  with  the
i
2
aevelopment  of  intestinal  strictures  and  increased  risk  for
urgery.8
The  results  of  surgery  in  children  with  CD  are  largely
ated  from  the  1980s  and  early  1990s,  a  period  in  which
mmunomodulators  were  not  widely  used  and  biological
herapy  had  not  yet  begun.
Elective  surgery  is  generally  advocated  in  children  with
rowth  failure  not  responding  to  medical  therapy  and/or
tricturing  disease.  Despite  the  relative  frequency  of  surgery
n  children  with  CD,  there  is  a  paucity  of  publications  repor-
ing  outcomes  and  describing  the  results  of  minimal  access
echniques.9--11 Recent  pediatric  studies  have  reported  a
ide  range  of  postoperative  recurrence  rate,  between  18%
nd  94%,  possibly  reﬂecting  different  clinical  settings,  treat-
ent  protocols  and  surveillance  after  surgery.10,12--14
The  aim  of  the  present  study  was  to  characterize  the
linical  proﬁle  and  the  clinical  outcome  of  children  and
dolescents  with  CD,  who  underwent  surgical  intervention
ithin  the  last  11  years  period  in  a  tertiary  referral  center.
. Materials and methods
his  was  a  retrospective,  cross-sectional  study,  including
ediatric  patients  less  than  18  years  with  the  diagnosisng  intra-abdominal  surgery  in  our  unit  between  January
004  and  December  2014.  All  patients  were  identiﬁed  from
 department  database  and  clinical  data  were  collected
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wSurgery  in  Pediatric  Crohn  Disease:  Case  Series  from  a  Single
from  patient  records.  A  standardized  protocol  has  been  used
before  and  after  surgery.  Date  of  diagnosis  was  taken  as
the  date  of  the  ﬁrst  endoscopy  with  histological  conﬁrma-
tion  of  the  disease.  Height,  weight  and  body  mass  index
(BMI)  were  converted  to  SD  scores  (SDS)  using  the  National
Center  for  Health  Statistics  international  growth  reference.
Growth  data  before  surgery  and  at  last  follow-up  were
compared  using  a  T  test,  with  signiﬁcance  considered  at
p  <  0.05.  Paris  phenotypic  classiﬁcation  immediately  before
surgery,  pre  and  postoperative  medical  therapy  and  type  of
surgery  were  recorded.  Clinical  response  was  assessed  by
Pediatric  Crohn’s  Disease  Activity  Index  (PCDAI)  at  baseline
and  at  last  follow-up  and  classiﬁed  into  3  categories:  clinical
remission  (PCDAI  <10),  relapse  (disease-free  time  with  sub-
sequent  rise  in  PCDAI  >10)  and  persistence  of  active  disease
(unabated  PCDAI  >12.5).  All  patients  undergoing  elective
intra-abdominal  surgery  underwent  preoperative  MRI  scans.
Endoscopic  evaluation  and  MRI  scans  were  done  approxi-
mately  one  year  after  surgery.  The  surgical  techniques  used
were  selected  according  to  surgical  team  experience.  Two
emergency  surgeries  were  performed  in  district  hospitals,  by
general  surgery  teams.  Major  surgery-related  complications
were  deﬁned  as  potentially  life-threatening,  with  the  need
of  re-intervention  or  hospital  stay  longer  than  twice  the
median  hospitalization  for  the  same  procedure.
3. Results
3.1.  Preoperative  evaluation
The  database  included  50  patients  diagnosed  with  CD  during
the  study  period;  eight  patients  underwent  surgery  (16%).
Table  1  summarizes  the  results.  Median  age  at  CD  diagno-
sis  was  12.0  years  (mean  12.4  ±  2.8  years;  range  7.9--17.1
years).  Paris  classiﬁcation:  CD  diagnosis  was  established
below  10  years  in  one  patient,  between  10  and  16  years  in
six  patients  and  at  17  years  in  one  patient.  Concerning  the
location  of  the  disease:  ileocolonic  (5),  colonic  (1),  upper
disease  (1),  ileocolonic/upper  disease  (1).  Regarding  the
disease  behavior,  classiﬁcation  was  as  follows:  stricturing
(4),  nonstricturing  nonpenetrating  (2),  penetrating  (1),  both
penetrating  and  stricturing  disease  (1).  Six  patients  had  no
evidence  of  growth  delay.  Three  patients  had  pubertal  delay
at  the  time  of  surgery.  Median  CD  index  activity  (PCDAI)
was  35.0  (mean  35  ±  13.2;  range  15--55)  indicating  a mod-
erate  activity  disease.  All  patients  started  partial/exclusive
enteral  nutrition  at  CD  diagnosis.  Mesalazine  was  used  in
ﬁve  patients  preoperatively,  thiopurines  in  six  and  steroids
in  three  patients.  Monoclonal  anti-TNF  therapy  (inﬂiximab
or  adalimumab)  was  used  in  four  patients.
3.2.  Surgery
Median  surgical  timing  was  2.9  years  after  CD  diagnosis
(mean  3.4  ±  2.5  years;  range  1.3--7.6  years).  Six  children
had  elective  surgery  based  on  clinical,  endoscopic,  imagi-
ological  ﬁndings  and  unresponsiveness  to  medical  therapy.
The  most  common  indication  for  elective  surgery  was
stricturing  or  penetrating  disease  (n  =  6);  one  child  had
additionally  intestinal  suboclusion.  Two  patients  developed
an  acute  abdomen  and  required  emergency  surgery  for
2
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ife-threatening  conditions.  Emergency  surgery  was  due
o:  ileocecal  abscess  with  ileal  perforation  and  peritoni-
is  (n  =  1)  and  acute  appendicitis/peritonitis  (n  =  1).  In  this
ast  patient,  the  diagnosis  of  CD  was  made  on  the  day
f  surgery.  Surgical  procedures  performed  are  summarized
n  Table  1  and  included:  partial  ileal  resection  (n  =  3),
leocecal  resection  (n  =  3),  ileal  plus  right  hemicolectomy
n  =  2).  The  extension  of  resected  ileum  ranged  between
0  and  45  cm  in  the  3/8  patients  with  available  data.
ll  surgeries  took  place  without  major  complications.  No
aparoscopic/stricturoplasty  procedures  were  performed  in
his  series.
.3.  Postoperative  course
edian  follow-up  time  was  1.7  years  (mean  2.4  ±  2.2  years;
ange  0.2  months  to  7.0  years).  Five  children  received
nti-TNF  therapy  and  three  children  received  thiopurines
s  maintenance  therapy  postoperatively  (one  patient  was
reated  simultaneously  with  anti-TNF  plus  thiopurine).
uring  the  follow-up  period,  all  patients  performed  post-
peratively  endoscopic  evaluation  at  a  median  period  of  1.5
ears  (mean  1.7  years  ±  0.8  years;  range  1.0  months  to  2.7
ears),  except  the  two  patients  in  which  follow-up  period
as  less  than  6  months;  ﬁve  patients  presented  endoscopic
emission  and  the  remained  patient  presented  mild  endo-
copic  activity.  Postoperatively  MRI  was  performed  in  three
atients,  within  a  median  period  of  one  year,  and  no  disease
ctivity  was  observed.
One  patient  (Patient  1)  had  clinical  and  endoscopic
elapse,  3.2  years  following  surgery.  In  this  patient,  evidence
f  disease  at  the  resection  margin  had  not  been  observed.
Median  PCDAI  at  the  last  evaluation  was  6.3  (mean
.9  ±  8.0;  range  0--25).  Height  and  weight  SDS  signiﬁ-
antly  increased  between  surgery  and  the  latest  follow-up
p  <  0.05),  although  no  signiﬁcant  increase  in  BMI  SDS  has
een  observed  (p  =  0.07)  (Fig.  1).  The  three  children  who
ad  prepubertal  stages  evolved  in  their  puberty  status  after
urgery.
.  Discussion
he  present  study  reﬂects  the  experience  of  a  single  ter-
iary  center  over  a 10-year  period,  representing  a  national
ase  series  concerning  speciﬁcally  surgery  in  pediatric  CD
atients.
The  natural  history  of  pediatric  CD  often  includes  bowel
urgery  even  in  the  biological  therapy  era.  However,  there
s  a  wide  range  of  surgery  rate  in  the  literature,  depend-
ng  on  the  studied  population.  Two  recent  pediatric  studies
rom  tertiary  referral  centers,  reported  a  median  interval
rom  diagnosis  to  ﬁrst  surgery  of  9  months  and  1.9  years,
espectively.9,11 In  our  series  the  whole  surgery  rate  of  16%
as  relatively  low,  as  compared  to  other  pediatric  series.
n  fact,  intra-abdominal  surgery  in  our  cohort  might  have
een  performed  relatively  late  in  the  course  of  disease,
ith  a  median  interval  from  diagnosis  to  intervention  of
.9  years,  which  may  reﬂect  the  recent  impact  of  biological
herapy  use.  However,  the  age  of  presentation  (12.0  years)
nd  disease  location  at  diagnosis  were  both  similar  to  other
eported  series.16,17
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Table  1  Table  summarizing  the  results.
Patient  1  ♂ 2  ♀ 3  ♀ 4  ♀ 5  ♂ 6  ♀ 7  ♀ 8  ♀
Paris  classiﬁcation  A1bL3B2G1  A1bL4bB2G0  A1bL3B2B3G0  A1bL3B2G1  A1aL3L4aB2G0  A1bL3B1G0  A2L3B3G0  A1bL2B1G0
Age of  CD  diagnosis  (years)  11.4  15.1  12.8  11.3  7.9  10.7  17.1  12.6
Surgery timing  after  diagnosis
(years)
5.1  2.9  3.0  5.5  7.6  1.5  1.3  --
Follow-up period  (years)  3.5  1.6  3.2  1.8  0.6  7.0  0.2  1.5
Preoperatively therapy  5-ASA
AZA
Pred
5-ASA
AZA
Pred
5-ASA
AZA
INF
AZA
INF
5-ASA
AZA
ADA
5-ASA
AZA
INF
Pred
--
Type  of  surgery  (resection  plus
end-to-end  anastomosis)
Distal  ileum
(30  cm)
Distal  ileuma Distal
ileum  +  cecuma
Distal
ileum  +  cecum
(45  cm)
Distal
ileum  +  cecuma
Distal
ileum  +  right
hemicolectomya,b
Distal  ileum
(30  cm)c
Distal
ileum  +  right
hemicolectomyd
PCDAI  (baseline/last  follow  up)  30  →  25  40  →  7.5  25  →  0  45  →  7.5  35  →  5  15  →  2.5  55  →  7.5  --  →  0
Clinical response  Recurrence  Clinical
remission
Clinical
remission
Clinical
remission
Clinical
remission
Clinical
remission
Clinical
remission
Clinical
remission
Postoperatively  endoscopic
evaluation
Endoscopic
remission
Endoscopic
remission
Endoscopic
remission
Mild  active
disease
NA  Endoscopic
remission
NA  Endoscopic
remission
Postoperatively endoscopic
evaluation  timing  after
surgery  (years)
2.5  1.0  2.1  1.0  NA  2.7  NA  1.0
Postoperatively MRI  scan
evaluation
NR  NR  Imaging
remission
Imaging
remission
NA  NR  NA  Imaging
remission
Postoperatively MRI  scan
evaluation  timing  after
surgery  (years)
NA  NA  1.4  0.9  NA  NA  NA  0.5
Delayed puberty  (Tanner  Stage
pre/postoperatively)
Stage
2  →  Stage  5
NA  Stage
2  →  Stage  5
Stage
3  →  Stage  5
NA  NA  NA  NA
Postoperatively therapy  5-ASA
AZA
INF
INF  5-ASA
AZA
INF  ADA  AZA
5-ASA
INF  5-ASA
ADA: adalimumab; Aza: azathioprine; BMI: body mass index; INF: inﬂiximab; NA: not applicable; NR: no realized; Pred: prednisolone; 5-ASA: mesalazine.
a Extension of resection not reported.
b Emergency surgery due to ileocecal abscess with ileal perforation and peritonitis.
c First intestinal resection one year before the CD diagnosis, as a suspected acute appendicitis.
d Emergency surgery due to peritonitis. CD diagnosis based on the histological examination of the surgical specimen.
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the  maintenance  of  clinical  remission,  allowing  a  disease-
free  interval  and  nutritional  recovery.  It  should  emphasizedFigure  1  Patients’  weight,  height  and  body  mass  in
Preoperative  therapy  most  commonly  involved  thiop-
urines  and  mesalazine.  Monoclonal  anti-TNF  therapy  before
surgery  was  used  in  half  of  the  patients.  When  looking  at
our  cohort  of  patients,  therefore,  the  question  of  whether
surgery  might  have  been  delayed  or  prevented  by  increased
use  of  biologic  agents  should  also  be  raised.  Considering  that
around  25%  of  pediatric  patients  with  CD  will  present  with
stricturing  disease,18 it  is  likely  that  a  subset  of  our  patients
will  develop  ﬁbrotic  strictures  which  are  unlikely  to  resolve
with  medical  treatment.  In  fact,  despites  the  use  of  more
intensive  medical  therapy  (including  biological  agents)  this
may  only  delay,  rather  than  avoid  surgery.19
However,  most  available  studies  do  not  report  the
impact  of  biological  agents  in  the  surgery  timing  and  clin-
ical  outcome.9,13 Although  in  our  series,  four  in  eight
patients  were  under  biologic  therapy,  surgery  was  ultimately
required,  reﬂecting  the  unavoidable  progressive  disease
behavior.  Biologic  therapy  was  not  used  in  remaining  four
patients,  concerning  the  earlier  study  period,  where  biologic
agents  were  not  yet  available.  In  fact,  this  feature  is  com-
mon  to  the  rare  pediatric  surgery  series,  mostly  including  a
low  rate  of  biological  therapy  use  (7--10%).9,13
An  additional  issue  concerning  the  use  of  biological
agents  in  young  patients  with  CD  is  the  development
of  antibodies,  and  subsequent  treatment  resistance  or
dependence.20 An  argument  exists,  therefore,  that  one
advantage  of  surgical  therapy  is  the  maintenance  of  treat-
ment  naivety,  retaining  a  useful  therapeutic  option  in  the
future.
Limitations  of  the  present  series  are  the  unavailability
of  data  concerning  the  extension  of  ileal  resection  in  ﬁve
of  eight  patients  and  the  fact  that  no  laparoscopic  stric-
turoplasty  was  performed.  Although  this  minimally  invasive
surgery/stricturoplasty  has  not  been  performed,  it  is  cur-
rently  considered  as  the  standard  technical  option  when
feasible,  particularly  in  limited  ileal  disease.
Surprisingly,  the  two  patients  submitted  to  emergency
surgery  had  a  disease  previously  evaluated  as  nonpenetrat-
ing  nonstricturing.
Although  no  major  complications  have  occurred  in  our
series,  the  small  number  of  patients  should  be  taken  into
account.  In  a  large  study  from  a  regional  center  including  69
patients,  a  29%  complication  rate  was  reported.9
According  to  ECCO/ESPGHAN  guidelines21 endoscopic
investigation  should  be  done  six  months  to  one  year  after
surgery  to  evaluate  the  effectiveness  of  the  surgery  and
redeﬁne  therapeutic  strategy.  In  this  small  cohort  the  post-
operative  endoscopic  evaluation  was  performed  a  little  later
t
t
s
mSD  scores  (SDS)  pre-surgery  and  at  latest  follow-up.
han  the  recommended  period,  and  only  three  patients
nderwent  MRI  scan  reﬂecting  organizational  limitations.
he  clinical  relapse  rate  of  12.5%  (one  in  eight  patients)  at
 median  follow-up  of  1.7  years  in  our  series  is  also  con-
istent  with  that  reported  in  the  literature,13 concerning
hort/medium  follow-up,  although  it  is  scarcely  documented
n  surgical  series.  Expectedly,  the  recurrence  rate  increases
ith  duration  of  follow-up,  attaining  rates  as  high  as  94%  at
0  years  follow-up.10 Both  clinical  behavior  (predominantly
leal  restricted  disease)  and  relatively  low  activity  index  in
ome  patients  might  have  contributed  to  the  low  recurrence
ate  in  this  series.  Davies  et  al.  reported  that  outcome  after
urgery  for  CD  in  children  is  mainly  related  to  disease  loca-
ion,  but  is  also  inﬂuenced  by  the  type  of  primary  operation
erformed.  In  this  study,  concerning  pre-biological  agents
ra,  anatomical  location  of  disease,  indication  for  surgery,
nd  preoperative  duration  of  symptomatic  disease,  were  the
nly  factors  that  signiﬁcantly  inﬂuenced  the  duration  of  the
ecurrence-free  interval.22
The  timing  of  surgery  is  crucial,  because  surgery  can  offer
 disease-free  interval  to  ensure  normal  growth  and  devel-
pment  when  performed  before  late  puberty.11,23 Growth
elay  leading  to  delayed  puberty  is  recognized  as  a  common
omplication  of  CD  in  the  pediatric  population.  Our  data
re  consistent  with  these  observations,  showing  an  improve-
ent  of  weight  and  catch-up-growth.  However,  in  a  recent
tudy  involving  a  large  number  of  patients  no  increase  in
eight  was  observed.9 Interestingly,  epidemiological  data
uggests  a  growth  advantage  of  early  surgery,  with  a  recently
ublished  cohort  of  patients  demonstrating  better  catch-up-
rowth  in  patients  operated  within  3  years  of  diagnosis.11
hus  this  issue  deserves  further  elucidation.
.  Conclusion
espite  the  small  size  of  the  present  cohort  (single  center
tudy)  and  the  relatively  short  follow-up  period,  data  from
he  present  study  are  consistent  with  the  evidence  that  sur-
ical  treatment  of  CD  is  a  valid  alternative  in  selected  cases,
ontributing  to  the  resolution  of  acute  complications  and  tohat  surgical  decisions  should  be  taken  by  a  multidisciplinary
eam,  at  an  early  stage  of  disease  and  ideally  involving
urgical  teams  from  reference  centers,  with  experience  in
inimally  invasive/laparoscopic  surgery  techniques.
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